TrialResults - center - Clinical trials results database in

You are here: Home > Search and browse > Browse treatment > rosuvastatin summary table

Table summary of clinical trials for rosuvastatin pdf short list

Clinical trials of rosuvastatin (Crestor) are available for the clinical conditions:

Cardiovascular prevention

These trials are included in meta-analysis concerning: cholesterol lowering intervention in all chronical situations, cholesterol lowering intervention in women, cholesterol lowering intervention in patient with related disease, cholesterol lowering intervention in elderly, cholesterol lowering intervention in patients with renal insufficiency (on hemodialysis or transplant), cholesterol lowering intervention in high risk patients with or without LDL cholesterol elevation, cholesterol lowering intervention in primary prevention,

Rosuvastatin vs control

ASTEROID (ongoing)

versus

Follow-up:

rosuvastatin vs placebo

JUPITER (sub group) ,2009

rosuvastatin 20mg daily
versus
placebo

healthy individuals aged >=70 years with normal LDL cholesterols but with CRP levels >=2.0 mg/dL

Follow-up: double-blind
double blind

JUPITER ,2008
NCT00239681

rosuvastatin 20 mg daily
versus
placebo

apparently healthy individuals with low LDL-cholesterol levels of less than 130 mg per deciliter but elevated C-reactive-protein (high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher)

Follow-up: median 1.9 year
double blind
26 countries

ASTRONOMER ,2010
ISRCTN 32424163

rosuvastatin 40 mg daily
versus
placebo

asymptomatic patients with mild to moderate aortic stenosis and no clinical indications for cholesterol lowering

Follow-up: 3.5 y
double blind

METEOR ,2007
NCT00225589

rosuvastatin 40mg daily
versus
placebo

individuals, with either age (mean, 57 years) as the only coronary heart disease risk factor or a 10-year Framingham risk score of less than 10%, modest CIMT thickening (1.2-<3.5 mm), and elevated LDL cholesterol

Follow-up:
double-blind
USA, Europe

CORONA ,2007
NCT00206310

rosuvastatin 10mg/d
versus
placebo

patients at least 60 years of age with NYHA class II, III, or IV ischemic, systolic heart failure

Follow-up: 32.9 months median
double blind

Krum ,2007

rosuvastatine 40mg/d
versus
placebo

patients with systolic (LVEF<40%) CHF of ischemic or nonischemic etiology

Follow-up: 6 months
double blind
Australia

GISSI-HF rosuvastatine ,2008
NCT00336336

low-dose rosuvastatin 10 mg daily
versus
placebo

Patients with NYHA classes II to IV heart failure, whatever the cause and the LVEF and already receiving optimized recommended therapy with no clear indication or contraindication to cholesterollowering therapy

Follow-up: 3.9y median (IQR 3-4.4)
double blind
Italy

AURORA ,2009

rosuvastatin 10 mg daily
versus
placebo

in patients with end-stage renal disease on hemodialysis

Follow-up: 3.2 y mean (max 5.6y)
double blind

JUPITER (women subgroup) ,2008

Rosuvastatin 20 mg daily
versus
placebo

apparently healthy men and women with low-density lipoprotein cholesterol levels of less than 130 mg/dL and high-sensitivity C-reactive protein levels of 2.0 mg/L or higher - subgroup of women

Follow-up: 1.9 y
double-blind
26 countries

Heart failure

These trials are included in meta-analysis concerning: cholesterol lowering intervention in all type of patients, cholesterol lowering intervention in elderly,